, /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Shareholders who purchased shares of GRTS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: to The complaint that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the Company would be unable to launch the Phase CORAL Study, it's approved COVID-19 vaccine, in the timeframe it had represented to investors; (ii) the foregoing would impair Gritstone's ability to obtain external funding in connection with the Study, thereby negatively affecting Gritstone's ability to maintain its balance sheet and cash position; (iii) accordingly, Gritstone overstated its ability to successfully develop and commercialize its products; (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Shareholders should not delay in registering for this class action. Register your information here: Once you register as a shareholder who purchased shares of GRTS during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is .
There is no cost or obligation to you to participate in this case. The Gross L.